Today, we’re proud to share that Glooko has been named the winner of the 2026 MedTech Breakthrough Award for “Best Overall MedTech Software.”
This recognition is meaningful because it reflects the breadth of what our teams are building: software designed to make diabetes and glycemic management simpler, more connected, and more actionable for the people and healthcare teams who rely on it every day.
Diabetes care generates an enormous amount of data. For people living with diabetes, that data can come from glucose meters, CGMs, insulin pumps, connected pens, activity trackers, food logging, blood pressure readings, and more. For clinicians, hospitals, and health systems, the challenge is not simply having more data — it is making that data useful, accessible, secure, and actionable inside real clinical workflows.
That is where Glooko is focused. Our portfolio spans the Glooko outpatient diabetes management platform, the Glooko Mobile App, Glooko XT in France, and EndoTool for inpatient glycemic management. Each solution supports a different part of the diabetes and glycemic management journey, but all are grounded in the same purpose: simplifying care, strengthening connections, and helping people and care teams make more informed decisions.
Making diabetes data easier to use
The outpatient Glooko diabetes management platform is designed to help care teams bring diabetes data together in one place. By connecting with more than 200 diabetes and health monitoring devices and apps and integrating into EHR workflows, Glooko helps reduce platform switching and gives providers a more complete view of their patients’ health data. That matters because every minute spent hunting for data is time taken away from patient care.
Supporting people with diabetes between visits
For people living with diabetes, the Glooko Mobile App helps make day-to-day management more approachable. Users can sync and view their health data, review trends, log information, and securely share data with their care teams. The goal is to help people better understand what is affecting their diabetes and support collaboration beyond the clinic visit.
Extending the portfolio across care settings
The addition of the EndoTool Glucose Management System through Monarch Medical Technologies expanded Glooko’s portfolio into inpatient glycemic management. EndoTool is designed to assist clinicians in optimizing insulin dosing for hospitalized patients, and it reflects our broader commitment to supporting glycemic safety across care settings. As we continue building toward a more connected future, we are focused on doing so with the quality, regulatory discipline, and clinical rigor healthcare demands.
A global approach with local needs in mind
Glooko XT, our remote patient monitoring solution in France, reflects another important part of our work: adapting digital health solutions to local healthcare landscapes, regulations, and patient needs. Diabetes care is global, but healthcare delivery is local. Our software must be flexible enough to support both realities.
This recognition belongs to the team
Awards are moments to pause, but they are not endpoints. This MedTech Breakthrough recognition belongs to the teams across Glooko who build, support, secure, regulate, implement, and continuously improve our software. It also belongs to the clinicians, health systems, partners, and people with diabetes who challenge us to keep making diabetes care simpler and more connected.
We are honored to receive this award and excited for what comes next as we continue transforming diabetes and glycemic management across the care continuum.
Read the full announcement here.
Not all products are available in all countries. EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.